Introduction
============

Botulinum neurotoxin is responsible for botulism, a severe and deadly neuroparalytic disease. It is the most potent toxin known, with as little as 30--100 ng potentially fatal to a human adult ([@evt068-B16]). There are seven types of botulinum neurotoxin (types A--G), which are formed by the Gram-positive anaerobe *Clostridium botulinum* and some strains of *C. butyricum* and *C. baratii.* Types A, B, E, and F neurotoxins have been associated with human pathology ([@evt068-B1]; [@evt068-B15]). *Clostridium botulinum* is a heterogeneous species that comprises four phylogenetically and physiologically distinct bacteria (*C. botulinum* Groups I--IV), with Groups I and II associated with human botulism ([@evt068-B1]; [@evt068-B16]). Strains of Group I (proteolytic) *C. botulinum* form type A, B, or F neurotoxin, with many strains carrying genes for two neurotoxins, and in some cases also forming two neurotoxins. Strains of Group II (nonproteolytic) *C. botulinum* form type B, E, or F neurotoxins, but there are currently no reports of strains carrying more than one neurotoxin gene ([@evt068-B14]; [@evt068-B18]). One interpretation for this observation would be that horizontal transfer of the neurotoxin genes occurs less frequently in Group II *C. botulinum* than it does in Group I *C. botulinum*. Recent genetic analysis has identified a number of neurotoxin subtypes, with particular subtypes often found only in one Group of *C. botulinum* ([@evt068-B23]; [@evt068-B12]; [@evt068-B14]; [@evt068-B18])*.* For example, strains of Group II *C. botulinum* type F, which are the subject of this study, exclusively carry the type F6 neurotoxin gene, whereas strains of Group I *C. botulinum* type F carry a neurotoxin gene, which can be of types F1--F5, and strains of *C. baratii* all carry the type F7 neurotoxin gene ([@evt068-B19]).

The neurotoxin has several accessory proteins, the genes for which are adjacent and form the so-called neurotoxin gene cluster. There are two classes; the *ha*-cluster encodes the neurotoxin, a nontoxic-nonhaemagglutinin protein, and three hemagglutinins; and the *orf-x*-cluster encodes the neurotoxin, a nontoxic-nonhaemagglutinin protein, and four other proteins (Orf-X1, Orf-X2, Orf-X3, and P47) of unknown function ([@evt068-B13]; [@evt068-B16]; [@evt068-B18]). In addition, clusters often contain the gene for a regulatory sigma factor, *botR*. When chromosomally located, botulinum neurotoxin gene clusters are usually flanked by fragments of mobile elements, an observation which has raised the possibility that they may have been acquired by horizontal gene transfer ([@evt068-B21]). Neurotoxin gene clusters can also be located on bacteriophages (Group III *C. botulinum*) and plasmids (Groups I, II, and IV). Horizontal acquisition of neurotoxin gene clusters must occur relatively rarely on an evolutionary timescale, based on the knowledge that in Group I, *C. botulinum* neurotoxin gene clusters are found at only three different chromosomal locations, and more dramatically in both Group II *C. botulinum* type E and in *C. butyricum* type E, the neurotoxin gene cluster has been inserted directly into *rarA*, a recombination-associated gene ([@evt068-B13]).

Recent work in our laboratory studied the genetic relationship between members of Group II *C. botulinum* using a whole-genome DNA microarray. This study extended the observations of others that strains of Group II *C. botulinum* type B and type F are closely related but that Group II *C. botulinum* type E strains form a distinct clade ([@evt068-B26]). Reference genome sequences were already available for Group II *C. botulinum* type B (Eklund17B) and type E (strains Beluga and Alaska), so we decided to sequence the genome of each type F strain from our microarray study to explain this close relationship with type B strains.

Materials and Methods
=====================

Bacterial Strains and Growth
----------------------------

Five strains of Group II (nonproteolytic) *C. botulinum* type F were used in this study ([table 1](#evt068-T1){ref-type="table"}). Three historical strains have been widely studied by previous authors, whereas two strains were recently isolated from scallops ([@evt068-B17]). Before use, all strains were checked for purity by growth on peptone-yeast-glucose-starch (PYGS) and reinforced clostridial medium with 5% (w/v) skim milk agar plates incubated under aerobic and anaerobic atmospheres ([@evt068-B4]). Table 1Strains of Group II (Nonproteolytic) *Clostridium botulinum* Type F6 Used in This StudyStrainMaterial from Which Strain Isolated (Country, Year)Received fromEklund 202FPacific sediments (CA, the United States, 1965)J. Crowther (Unilever Research)Hobbs FT10Atlantic Herring from Moray Firth (Scotland, UK, 1970s)J. Crowther (Unilever Research)Craig 610Salmon from Columbia River (OR, the United States, 1965)J. Crowther (Unilever Research)IFR 06/001Scallops (Canada, 2006)Isolated at IFRIFR 06/005Scallops (Canada, 2006)Isolated at IFR

DNA Preparation and Sequencing
------------------------------

Genomic DNA was purified from exponentially growing cells cultured in PYGS medium as described previously ([@evt068-B5]). Library construction and genome sequencing was carried out by The Genome Analysis Centre (TGAC), Norwich Research Park, UK, on the Illumina MiSeq platform, which produces longer sequencing reads than previous Illumina platforms (MiSeq Personal Sequencer, Illumina at <http://www.illumina.com/systems/miseq.ilmn>, last accessed May 21, 2013). Reads were assembled using the short-read assembler ABySS ([@evt068-B22]) with custom in house refinements. All sequencing reads were assembled to generate an improved high-quality draft sequence ([@evt068-B7]).

Sequence Analysis
-----------------

Sequences were loaded into Vector NTI Advance 11 (Invitrogen), and for each genome, the contig that contained the type F6 toxin gene cluster was identified. Pairwise alignments of homologous contig regions were performed using the Vector NTI program AlignX, which uses the ClustalW algorithm. The Artemis Comparison Tool (ACT) was used for whole-genome comparisons ([@evt068-B6]). Open reading frames (ORFs) of minimum 150-bp length, identified using standard Vector NTI software set to use ATG, GTG, and TTG start codons were annotated using BLASTn, BLASTp, and domain enhanced lookup time accelerated (DELTA)-Basic Local Alignment Search Tool (BLAST) programs from the National Center for Biotechnology Information (NCBI) website (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>, last accessed May 21, 2013). Predicted coding sequences (CDSs) were not included in the annotation if they showed no obvious homology to known CDSs or gene products and had no obvious ribosome binding sites upstream of any start codon. GenBank accession numbers for each 50-kb region are KC516868 (IFR 06/001), KC516869 (IFR 06/005), KC516870 (Craig 610), KC516871 (Eklund 202F), and KC516872 (Hobbs FT10).

Analysis of Group II *C. botulinum* Type F6 Neurotoxin Gene Cluster Locus
=========================================================================

DNA sequences of five different strains of Group II *C. botulinum* type F6 ([table 1](#evt068-T1){ref-type="table"}) were assembled into contigs from Illumina MiSeq data. Contig analysis using the ACT confirmed our microarray results ([@evt068-B26]) by showing that the majority of the Group II *C. botulinum* type F6 genome is very similar in content and organization to that of the Group II *C. botulinum* type B strain Eklund17B and rather less similar to that of Group II *C. botulinum* type E strains Alaska and Beluga. This is exemplified in [figure 1](#evt068-F1){ref-type="fig"}, in which an ACT comparison between regions of chromosomal DNA of strains Eklund17B, IFR 06/001, and Alaska demonstrates the reduced synteny with the latter strain. There was no evidence for the type F neurotoxin gene cluster being carried by a plasmid. F[ig]{.smallcaps}. 1.---Group II *Clostridium botulinum* chromosomal DNA ACT comparisons of the 50-kb neurotoxin cluster locus of type F6 strain IFR 06/001 (*B*) with type B strain Eklund17B (*A*) and type E strain Alaska (*C*). Red bars denote regions sharing a high degree of sequence identity; the two thinner red bars linking section A with B are due to homology between the two versions of the *topB* gene, one present as a newly acquired gene, one as the original disrupted version. A similar duplication of homology is seen for the *topB* gene (CLH_1538) of Alaska (*C,* box i). Color code for features: 1) red, neurotoxin gene/cluster sequence; 2) blue, bacteriophage DNA; 3) purple, plasmid DNA; 4) yellow, IS4 elements; and 5) green and black, sequences unrelated to mobile DNA elements or toxin cluster genes, with black features apparently acquired horizontally. Boxes lacking arrowheads represent features with disrupted ORFs. Greatest synteny is seen between strain 06/001 (*B*) and Eklund17B (*A*): CDS/features 1--8 and 36--42 are homologs of Eklund17B (NRP \[Norwich Research Park\]) CDSs CB17B1604-1610 and CB17B1610-1617 (all sharing \>90% identity). CDS 12 (in black): newly introduced *topB* gene. CDSs 19--24: neurotoxin cluster genes *orf-x3*, *orf-x2*, *orf-x1*, *p47*, nontoxic--nonhemagglutinin gene, and type F6 neurotoxin gene, respectively. Features 32 and 35 (red boxes): fragments of type B neurotoxin gene and type E neurotoxin gene, respectively. Chromosomal regions of type E strain Alaska homologous to the 50-kb toxin cluster locus of strain 06/001 are scattered due to poorer synteny; three main regions are depicted (section C). Box i: genes CLH_1532-1548, (88--96% identity). Box ii: CLH_1115-1105 (79--90% identity, note lack of homology with *orf-x2*, CLH_1114). Box iii: CLH_1908-1901 (95--96% identity). The type E3 neurotoxin gene of Alaska, CLH_1110 shares homology with strain 06/001 at two locations; the 3′-end of the type F6 neurotoxin gene (CDS 24) plus the nonfunctional type E neurotoxin gene fragment (feature 35).

A 50-kb region from each *C. botulinum* type F6 genome containing the neurotoxin gene cluster was compared. Apart from 10 single-nucleotide polymorphisms (SNPs) and one 15-bp deletion, all 50-kb sequences were identical, suggesting that Group II *C. botulinum* type F strains are clonal, deriving from one rare event. All sequence differences mapped to the Eklund 202F genome ([table 2](#evt068-T2){ref-type="table"}); this agrees with observations made by [@evt068-B11] using pulsed-field gel electrophoresis, also [@evt068-B19] using 16S rRNA sequencing that Eklund 202F differs slightly from other Group II *C. botulinum* type F strains. In our recent comparative genomic microarray analysis, Eklund 202F was also found to be slightly divergent from other Group II *C. botulinum* type F strains ([@evt068-B26]). Table 2Sequence Differences within Strains of Group II *Clostridium botulinum* Type F6SNP/DeletionCo-OrdinateGeneT-C68IntergenicG-A529Sensory transduction protein kinaseT-A1,855Sensory transduction protein kinaseC-T1,938Sensory transduction protein kinaseA-G5,582IntergenicA-G29,314Type F6 neurotoxinATGATTTTGAAGAAG (deletion)36,850--36,8645′-flank of type B neurotoxin fragmentG-A40,549IntergenicC-T47,283Exonuclease/helicaseA-C48,699MATE efflux family proteinA-G49,015MATE efflux family protein[^3]

Each of these 50-kb regions contains an apparently foreign insertion of 34.4-kb DNA sequence, which has disrupted the *topB* gene, encoding DNA topoisomerase III ([fig. 1](#evt068-F1){ref-type="fig"}*B*). This enzyme decatenates the newly replicated bacterial chromosome and is essential for survival. In the other Group II *C. botulinum* genomes currently available in databases (Eklund17B, Beluga, Alaska), only one copy of *topB* exists. Comparison with closely related *topB* sequences showed that although the type F6 *topB* is split by the 34.4-kb inserted DNA, the full CDS is still present; the N-terminal 109 codons border the 5′-flank of the DNA insertion, whereas its 3′-flank is defined by the remaining 620 codons. Thus, the original foreign DNA acquisition event did not rearrange or duplicate the sequence of the target site. The disrupted *topB* was found to have been replaced by a new copy, carried within the inserted DNA (see later). Percent G + C was analyzed and did not vary any more within the 34.4-kb region than it did in the flanking regions (data not shown). This suggests that the new DNA is the result of homeologous horizontal gene transfer(s), that is, it has been acquired from an organism closely related to the recipient rather than from a completely unrelated bacterium ([@evt068-B9]).

Predicted CDSs within the 34.4-kb foreign DNA were examined for evidence of the history of the insertion event ([fig. 1](#evt068-F1){ref-type="fig"}*B*). Prime suspects at its 5′-end were three contiguous regions encoding site-specific recombinases/bacteriophage integrases or remnants thereof (CDSs 9--11, [fig. 1](#evt068-F1){ref-type="fig"}*B*). Significantly, after a short interval (529 bp) is an intact *topB* gene (CDS 12, [fig. 1](#evt068-F1){ref-type="fig"}*B*), presumably replacing the function of the disrupted copy. Most interestingly, this *topB* gene is more closely related to those of *C. beijerinckii* (76% amino acid identity) and *C. butyricum* (75% amino acid identity) than to those of Group II *C. botulinum*. The insertion of neurotoxin cluster DNA into a gene together with replacement of the same gene by another copy has precedent; as mentioned earlier in Group II *C. botulinum* type E and *C. butyricum* type E strains, the location of the type E neurotoxin gene cluster appears to be the result of insertion events that split the *rarA* gene at codon 102 in both species ([@evt068-B13]). The *rarA* gene product is a resolvase involved in recombination or transposon insertion events, and [@evt068-B13] speculated that this might have played a part in these two independent insertion events. Is it possible that the *topB* gene, whose product is also involved in DNA manipulation, may have acted as a target for foreign DNA insertion via a similar mechanism? Intriguingly, BLAST results for the most 5′ of the three integrase-like CDSs (CDS 9, [fig. 1](#evt068-F1){ref-type="fig"}*B*) of the newly acquired piece of DNA suggest that its gene product is a member of the XerD family, which in *Escherichia coli* acts in concert with XerC to perform a similar function to that of TopB, that is, conversion of dimeric chromosomes into monomers ([@evt068-B2]).

Located 4.2 kb after the intact *topB* gene is a type F6 neurotoxin gene in a complete *orf-x*-cluster (CDSs 19--24, [fig. 1](#evt068-F1){ref-type="fig"}*B*), identical in organization to that described by [@evt068-B8] for the Group II *C. botulinum* type F6 strain IBCA66-5436. All the type F6 strains described in this study, together with IBCA66-5436 and all Group II *C. botulinum* type E neurotoxin clusters lack the sigma factor *botR* gene. Interestingly, *botR* is present in the *orf-x*-cluster of the Group I *C. botulinum* type F strains Langeland and 230613 ([@evt068-B13]; [@evt068-B25]), but its presence and position in the *orf-x*-cluster of *C. baratii* type F has yet to be established ([@evt068-B19]). The neurotoxin gene cluster in the Group II *C. botulinum* type F described in this study spans 13.55 kb from the 3′-end of the *orf-x3* gene to the 3′-end of the type F6 neurotoxin gene. It is flanked at its 5′-end by two IS4 element-related regions (CDSs 17, 18) and at its 3′-end by remnants of a bacteriophage integrase/recombinase (CDS 26, [fig. 1](#evt068-F1){ref-type="fig"}*B*). The type F6 neurotoxin genes in strains Hobbs FT10, Craig 610, IFR 06/001, and IFR 06/005 were identical, whereas strains Eklund 202F and IBCA66-5436 share a single SNP in the 27th codon where there is an A--G transition changing an AAA (lysine) codon to a GAA (glutamate) codon ([table 2](#evt068-T2){ref-type="table"}). Except for this one SNP, the remainder of the neurotoxin gene cluster is identical for the five type F6 strains examined in this study and for IBCA66-5436. This high similarity of the neurotoxin gene cluster implies that strain IBCA66-5436 will also fall into this same clonal group. Indeed, 16S rRNA sequence data places IBCA66-5436 in the same clade as Hobbs FT10 and Craig 610 ([@evt068-B19]).

Only 3.7 kb from the type F6 gene is a 1 kb CDS that begins with sequence distantly related to a phage integrase; unexpectedly, BLASTp hits for the predicted product of a 270-codon region further downstream were to the receptor binding domain of the botulinum neurotoxin heavy chain (Feature 32, [fig. 1](#evt068-F1){ref-type="fig"}*B*). The top three hits were to type G neurotoxin, associated with strains of Group IV *C. botulinum* (*C. argentinense*) ([@evt068-B24]); however, the amino acid identity was only 35%, with 22 gaps. Because the query sequence contained conserved domains, DELTA-BLAST was used. This makes use of a subset of the NCBI's Conserved Domain Database and should produce better quality alignments ([@evt068-B3]). Using DELTA-BLAST, all the top hits (30% identity but only 18 gaps) were to the heavy chain of type B neurotoxins, at residue positions approximately 1009--1291. Based on this evidence, the DNA sequence is annotated as deriving from a type B neurotoxin gene.

The 3′-end of the foreign DNA insertion bears further interesting evidence of recombination events. Located 242 bp after the type B neurotoxin gene fragment is a truncated (130 of the expected 170--190 codons) CDS for signal peptidase I, closely followed by a partially deleted IS4 sequence containing reading frame errors (CDSs 33, 34, [fig. 1](#evt068-F1){ref-type="fig"}*B*). The reconstructed IS4 ORF encodes 311 amino acid residues, for which the best BLASTp hits (52% identity) were to IS4 elements of *C. cellulovorans* 743B. The remains of IS mobile elements are often found associated with *C. botulinum* neurotoxin gene clusters, usually not only at their 5′- and 3′-flanks but also sometimes within the gene cluster itself ([@evt068-B13]), and are thought to indicate horizontal gene transfer activity. The fact that there are phage integrase genes at one end of the DNA insertion, and transposable element DNA at the other end, as is also the case for the intact type F6 neurotoxin cluster, makes it difficult to speculate on the exact mechanism for insertion of the foreign DNA as these two different mobile elements and the CDSs contained within their borders provide evidence for several such events in this region, not merely one.

Adjacent to the inactive IS4 element is a 736-bp fragment of DNA containing a disrupted ORF (Feature 35, [fig. 1](#evt068-F1){ref-type="fig"}*B*). After correction of reading frame errors, the original ORF encodes 247 amino acid residues with 81% identity to a type E neurotoxin (DELTA-BLAST alignment to residues 884--1,130 of most type E neurotoxins). The closest relatives to this type E fragment are the recently described type E9 neurotoxin of Group II *C. botulinum*, followed by the type E5 neurotoxin of *C. butyricum.* Interestingly, as with Group II *C. botulinum* type F6, the chromosomal DNA of the strain that forms type E9 neurotoxin was reported as being more closely related (99%) to that of Eklund17B than to other Group II *C. botulinum* type E strains (94%) ([@evt068-B20]).

Alignment of predicted peptides for the type B and type E gene fragments with complete type B and type E neurotoxin reference sequences shows that both of these fragments partially overlap, spanning approximately the same region of the neurotoxin heavy chain. This shows that a single neurotoxin gene from the ancestral gene cluster has not been disrupted by insertion of new DNA; rather, two completely different neurotoxin genes have been disrupted in successive rounds of recombination at this locus. The observations that the rest of the chromosome is most similar to that of a Group II *C. botulinum* type B, and that the CDS for the type B neurotoxin fragment is more degraded (30% amino acid identity) than that of the type E fragment (81% amino acid identity), suggests that the original bacterium was probably a Group II *C. botulinum* type B strain.

A further 335 bp after the type E gene fragment, the C-terminal fragment of the disrupted *topB* gene marks the end of the 34.4-kb DNA insertion and the return to synteny with Eklund17B (CDSs 36--42, [fig. 1](#evt068-F1){ref-type="fig"}*B*).

Because the CDSs that flank the 34.4-kb insertion show such close synteny with Eklund17B, it would be interesting to examine this region in other Group II *C. botulinum* strains for evidence of genetic recombination. Unfortunately, at present, nothing can be said regarding the frequency of use of this *topB* locus for insertion of neurotoxin gene clusters in Group II *C. botulinum* type B, as the only available genome is that of Eklund17B, which carries its neurotoxin gene cluster on a plasmid. In their study of plasmid borne neurotoxin gene clusters in Group I and Group II *C. botulinum* type B, [@evt068-B10] identified two other Group II type B strains, which bear their neurotoxin gene cluster on a plasmid, as do Group II *C. botulinum* type B strains CDC 3875 and IFR 05/025 that we have recently sequenced (data not shown).

Conclusions
===========

Although the type B and type E neurotoxin genes discovered in this study are incomplete, this report is the first to describe evidence of more than one neurotoxin gene in Group II *C. botulinum* and completely changes the view that members of this group are less recombinogenic than those of Group I, at least with respect to neurotoxin gene cluster sequences. We also identify the *topB* gene as a chromosomal locus for a *C. botulinum* neurotoxin gene cluster that has not been described previously.

The simplest explanation for the evolution of this type F6 clonal group is that the original ancestor was a Group II *C. botulinum* type B strain, either with a chromosomally located neurotoxin gene cluster or because all type B strains so far examined seem to possess a plasmid-based neurotoxin gene cluster, one where this cluster has integrated into the chromosome. This received DNA from a strain containing a type E gene cluster, followed by the most recent event, where a complete type F6 gene cluster was inserted. In each case, the previous neurotoxin gene was inactivated, so there still remains to be found a Group II *C. botulinum* bearing two functional neurotoxin genes, unlike the situation in Group I *C. botulinum* where several such strains are reported.

It should be emphasized that the above is only the simplest predicted course of events. At least two different types of mobile element have been involved in these genetic exchanges on at least two different occasions. Because the newly acquired *topB* gene is more like that from *C. butyricum* or *C. beijerinckii*, it is possible that not all partners in these DNA swapping events were *C. botulinum*. Genetic exchange between bacteria must be evidence that at some stage they shared an environment; Group II *C. botulinum*, *C. butyricum,* and *C. beijerinckii* are all saccharolytic anaerobes, so this speculation has at least some biological relevance.

It has been shown that members of Group II *C. botulinum* type F6 are closely related. The series of recombination events needed to deliver them has probably occurred just once to give a clonal group that has spread around the world. It is also possible that strains with evidence of other recombinational events at the *topB* hot spot exist but have not yet been described. Perhaps, the recently described Group II *C. botulinum* type E9 strain CDC 66177 ([@evt068-B20]), which has chromosomal DNA more closely related to that of Eklund17B than to other Group II *C. botulinum* type E strains mirrors one of the evolutionary stages of Group II *C. botulinum* type F6, although the insertion site in this case is again the *rarA* gene. To date, the only available genome sequence for Group II *C. botulinum* type E strains is for strains Alaska and Beluga, and these both lack evidence for the partial type B gene fragment described in this work. Further genetic clues to enable us to unravel the complex evolutionary route that has resulted in the present Group II *C. botulinum* type F6 strains will be uncovered as the genomes of more Group II *C. botulinum* are examined*.*
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